Zoledronic Acid Accord

Country: European Union

Language: Croatian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

monohidrat zoledronske kiseline

Available from:

Accord Healthcare S.L.U.

ATC code:

M05BA08

INN (International Name):

zoledronic acid

Therapeutic group:

bisfosfonati

Therapeutic area:

Hypercalcemia; Fractures, Bone; Cancer

Therapeutic indications:

Sprječavanje koštanih vezane uz događaje (patološki prijelomi, spinalne kompresije, zračenja ili operacije kosti ili hiperkalcijemije) u odraslih bolesnika s uznapredovalim zloćudnim bolestima koje uključuju kosti. Liječenje odraslih bolesnika s tumorom-induced гиперкальциемии (TPU).

Product summary:

Revision: 9

Authorization status:

odobren

Authorization date:

2014-01-16

Patient Information leaflet

                                27
B. UPUTA O LIJEKU
28
UPUTA O LIJEKU: INFORMACIJA ZA KORISNIKA
ZOLEDRONATNA KISELINA ACCORD 4 MG/5 ML KONCENTRAT ZA OTOPINU ZA
INFUZIJU
zoledronatna kiselina
PAŽLJIVO PROČITAJTE CIJELU UPUTU PRIJE NEGO POČNETE PRIMJENJIVATI
OVAJ LIJEK JER SADRŽI VAMA
VAŽNE PODATKE.
•
Sačuvajte ovu uputu. Možda ćete je trebati ponovno pročitati.
•
Ako imate dodatnih pitanja, obratite se liječniku, ljekarniku ili
medicinskoj sestri.
•
Ako primijetite bilo koju nuspojavu, potrebno je obavijestiti
liječnika, ljekarnika ili medicinsku
sestru. To uključuje i svaku moguću nuspojavu koja nije navedena u
ovoj uputi. Pogledajte dio
4.
ŠTO SE NALAZI U OVOJ UPUTI
1.
Što je Zoledronatna kiselina Accord i za što se koristi
2.
Što morate znati prije nego primite Zoledronatnu kiselinu Accord
3.
Kako primjenjivati Zoledronatnu kiselinu Accord
4.
Moguće nuspojave
5.
Kako čuvati Zoledronatnu kiselinu Accord
6.
Sadržaj pakiranja i druge informacije
1.
ŠTO JE ZOLEDRONATNA KISELINA ACCORD I ZA ŠTO SE KORISTI
Djelatna tvar u Zoledronatnoj kiselini Accord je zoledronatna
kiselina, koja pripada skupini tvari koje
se zovu bisfosfonati. Zoledronatna kiselina djeluje tako da se spaja
na kost i usporava brzinu
pregradnje kosti. Koristi se za:
•
SPRJEČAVANJE KOŠTANIH KOMPLIKACIJA
, npr. prijeloma, u odraslih bolesnika s koštanim
metastazama
(širenje raka iz primarnog mjesta u kosti).
•
SMANJENJE KOLIČINE KALCIJA
u krvi u odraslih bolesnika kad je količina kalcija prevelika zbog
prisutnosti tumora. Tumori mogu ubrzati normalnu pregradnju kosti,
zbog čega se kalcij
pojačano otpušta iz kostiju. To se stanje zove hiperkalcemija
izazvana tumorom.
2.
ŠTO MORATE ZNATI PRIJE NEGO PRIMITE ZOLEDRONATNU KISELINU ACCORD
Pažljivo slijedite sve upute koje ste dobili od liječnika.
Prije nego što počnete primati Zoledronatnu kiselinu Accord,
liječnik će Vam napraviti krvne pretrage
i u redovitim vremenskim razmacima provjeravati Vaš odgovor na
liječenje.
NE SMIJETE PRIMATI ZOLEDRONATNU KISELINU ACCORD:
•
ako dojite
•
ak
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOG I.
SAŽETAK OPISA SVOJSTAVA LIJEKA
2
1.
NAZIV LIJEKA
Zoledronatna kiselina Accord 4 mg/5 ml koncentrat za otopinu za
infuziju
2.
KVALITATIVNI I KVANTITATIVNI SASTAV
Jedna bočica s 5 ml koncentrata sadrži 4 mg zoledronatne kiseline (u
obliku hidrata).
Jedan ml koncentrata sadrži 0,8 mg zoledronatne kiseline (u obliku
hidrata).
Za cjeloviti popis pomoćnih tvari vidjeti dio 6.1.
3.
FARMACEUTSKI OBLIK
Koncentrat za otopinu za infuziju (sterilni koncentrat)
Bistra i bezbojna otopina.
4.
KLINIČKI PODACI
4.1
TERAPIJSKE INDIKACIJE
-
Sprječavanje koštanih događaja (patološki prijelomi, kompresija
kralježaka, zračenje ili
kirurški zahvat na kosti ili hiperkalcemija izazvana tumorom) u
odraslih bolesnika s
uznapredovalom zloćudnom bolešću koja je zahvatila kosti.
-
Liječenje odraslih bolesnika s hiperkalcemijom izazvanom tumorom.
4.2
DOZIRANJE I NAČIN PRIMJENE
Zoledronatnu kiselinu Accord bolesnicima smiju propisivati i
primjenjivati samo zdravstveni djelatnici
s iskustvom u intravenskoj primjeni bisfosfonata. Bolesnicima koji se
liječe Zoledronatnom kiselinom
Accord potrebno je dati Uputu o lijeku i karticu-podsjetnik za
bolesnika.
Doziranje
_Sprječavanje koštanih događaja u bolesnika s uznapredovalom
zloćudnom bolešću koja je zahvatila _
_kosti _
_Odrasli i starije osobe _
Preporučena doza za sprječavanje koštanih događaja u bolesnika s
uznapredovalom zloćudnom
bolešću koja je zahvatila kosti iznosi 4 mg zoledronatne kiseline
svaka 3 do 4 tjedna.
Bolesnicima također treba davati peroralni dodatak kalcija od 500 mg
i 400 IU vitamina D na dan.
Pri donošenju odluke da se liječe bolesnici s koštanim metastazama
radi sprječavanja koštanih
događaja treba uzeti u obzir da učinak liječenja nastupa nakon 2-3
mjeseca.
Liječenje hiperkalcemije izazvane tumorom
_Odrasli i starije osobe _
Preporučena doza kod hiperkalcemije (serumski kalcij korigiran za
albumin ≥ 12,0 mg/dl ili
3,0 mmol/l) je jednokratna doza od 4 mg zoledronatne kiseline.
Oštećenje funkcije bubrega
_Hiperkalcemij
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 24-01-2022
Summary of Product characteristics Summary of Product characteristics Bulgarian 24-01-2022
Public Assessment Report Public Assessment Report Bulgarian 15-03-2019
Patient Information leaflet Patient Information leaflet Spanish 24-01-2022
Public Assessment Report Public Assessment Report Spanish 15-03-2019
Patient Information leaflet Patient Information leaflet Czech 24-01-2022
Public Assessment Report Public Assessment Report Czech 15-03-2019
Patient Information leaflet Patient Information leaflet Danish 24-01-2022
Public Assessment Report Public Assessment Report Danish 15-03-2019
Patient Information leaflet Patient Information leaflet German 24-01-2022
Public Assessment Report Public Assessment Report German 15-03-2019
Patient Information leaflet Patient Information leaflet Estonian 24-01-2022
Public Assessment Report Public Assessment Report Estonian 15-03-2019
Patient Information leaflet Patient Information leaflet Greek 24-01-2022
Public Assessment Report Public Assessment Report Greek 15-03-2019
Patient Information leaflet Patient Information leaflet English 24-01-2022
Public Assessment Report Public Assessment Report English 15-03-2019
Patient Information leaflet Patient Information leaflet French 24-01-2022
Public Assessment Report Public Assessment Report French 15-03-2019
Patient Information leaflet Patient Information leaflet Italian 24-01-2022
Public Assessment Report Public Assessment Report Italian 15-03-2019
Patient Information leaflet Patient Information leaflet Latvian 24-01-2022
Public Assessment Report Public Assessment Report Latvian 15-03-2019
Patient Information leaflet Patient Information leaflet Lithuanian 24-01-2022
Summary of Product characteristics Summary of Product characteristics Lithuanian 24-01-2022
Public Assessment Report Public Assessment Report Lithuanian 15-03-2019
Patient Information leaflet Patient Information leaflet Hungarian 24-01-2022
Summary of Product characteristics Summary of Product characteristics Hungarian 24-01-2022
Public Assessment Report Public Assessment Report Hungarian 15-03-2019
Patient Information leaflet Patient Information leaflet Maltese 24-01-2022
Public Assessment Report Public Assessment Report Maltese 15-03-2019
Patient Information leaflet Patient Information leaflet Dutch 24-01-2022
Public Assessment Report Public Assessment Report Dutch 15-03-2019
Patient Information leaflet Patient Information leaflet Polish 24-01-2022
Public Assessment Report Public Assessment Report Polish 15-03-2019
Patient Information leaflet Patient Information leaflet Portuguese 24-01-2022
Summary of Product characteristics Summary of Product characteristics Portuguese 24-01-2022
Public Assessment Report Public Assessment Report Portuguese 15-03-2019
Patient Information leaflet Patient Information leaflet Romanian 24-01-2022
Public Assessment Report Public Assessment Report Romanian 15-03-2019
Patient Information leaflet Patient Information leaflet Slovak 24-01-2022
Public Assessment Report Public Assessment Report Slovak 15-03-2019
Patient Information leaflet Patient Information leaflet Slovenian 24-01-2022
Summary of Product characteristics Summary of Product characteristics Slovenian 24-01-2022
Public Assessment Report Public Assessment Report Slovenian 15-03-2019
Patient Information leaflet Patient Information leaflet Finnish 24-01-2022
Public Assessment Report Public Assessment Report Finnish 15-03-2019
Patient Information leaflet Patient Information leaflet Swedish 24-01-2022
Public Assessment Report Public Assessment Report Swedish 15-03-2019
Patient Information leaflet Patient Information leaflet Norwegian 24-01-2022
Summary of Product characteristics Summary of Product characteristics Norwegian 24-01-2022
Patient Information leaflet Patient Information leaflet Icelandic 24-01-2022
Summary of Product characteristics Summary of Product characteristics Icelandic 24-01-2022